Regeneron Pharmaceuticals and Alnylam Pharmaceuticals will work together to discover, develop and commercialise new RNA interference (RNAi) therapeutics for a broad range of diseases focused on ocular and central nervous system (CNS) diseases.
The collaboration will leverage both companies’ scientific and technological expertise and will build on Alnylam’s recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS.
The collaboration will also benefit from Regeneron’s VelociSuite technologies and capabilities from the Regeneron Genetics Centre (RGC).
Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases.
Regeneron will lead development and commercialisation for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments.
The companies will jointly advance and alternate leadership on CNS programs, with the lead party retaining global development and commercial responsibility.
For CNS programs, both companies will have the option at candidate selection to participate equally in potential future profits of programs led by the other party.
Regeneron has agreed to make a $400 million upfront payment to Alnylam and to purchase $400 million of Alnylam equity.
Alnylam is eligible to receive up to an additional $200 million in milestone payments upon achievement of certain criteria during early clinical development for the eye and CNS programs.
The companies plan to advance programs directed to 30 targets and introduce many into clinical development during the initial five-year discovery period, which includes an option to extend.
For each program, Regeneron will provide Alnylam with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, translating to the potential for approximately $30 million in annual discovery funding to Alnylam as the alliance reaches steady state.